Health Oct 08 How GLP-1s are reshaping cultural views on body image By Stephanie Sy, Mike Fritz, Sam Lane
Health Oct 06 Watch 8:48 High cost of GLP-1s drives some to seek cheaper, unregulated versions Despite some recent improvements, millions of Americans still face significant barriers in affording GLP-1s. At the same time, many patients have found alternative, cheaper paths to get their hands on unregulated versions. Stephanie Sy reports for our series, GLP-1s: Reshaping… By Stephanie Sy, Sam Lane, Mike Fritz
Health Oct 05 Watch 6:54 As GLP-1s reshape America, questions and new uses emerge Hailed by some as miracle drugs, GLP-1s have surged in popularity in the past few years. An estimated one out of every eight Americans is now on some version of them and scientists continue to research new potential uses. But… By William Brangham, Sam Lane, Mike Fritz
Health Jul 09 Watch 7:13 Some Medicare beneficiaries eligible for weight loss drug discounts The number of Americans taking a GLP-1 drug for weight loss is on the rise. A new Gallup poll shows 11% of adults say they are currently using one, a dramatic increase from just two years ago when just 3%… By William Brangham, Andrew Merlis, Solveig Rennan
Health Jun 19 Watch 7:40 Research shows weight-loss drugs may also reduce cancer risk A growing body of research suggests popular weight-loss drugs like Ozempic and Wegovy may also help treat or prevent certain cancers. It’s the latest unexpected benefit to be associated with GLP-1s, which are now taken by one-in-eight American adults. William… By William Brangham, Jackson Hudgins
Nov 06 Watch 7:10 The potential impact of lowering the cost of weight loss drugs By William Brangham, Jackson Hudgins, Jenna Bloom Millions of Americans will soon have direct access to popular weight-loss drugs at far lower prices than they pay now. That’s due to a deal announced between President Trump and pharmaceutical giants Eli Lilly and Novo Nordisk. William Brangham discussed… Continue watching
Oct 16 States are showing progress in reducing obesity, new report finds By JoNel Aleccia, Associated Press Cuts to federal staff and programs that address chronic disease could endanger that progress, according to a new report released Thursday. Continue reading
Apr 14 Pfizer abandons potential obesity treatment pill By Tom Murphy, Associated Press The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a possible drug-induced liver injury that ended once the person stopped taking the treatment. Continue reading
Mar 05 Novo Nordisk cuts Wegovy prices, following Eli Lilly on Zepbound By Associated Press The new monthly price of $499, down from $650, takes effect immediately. Continue reading
Feb 12 Study suggests obesity drugs could help with alcohol cravings By Carla K. Johnson, Associated Press A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol. Continue reading